Full Press Release Details
Acquisition of SentreHEART
MASON, Ohio (BUSINESS WIRE) August 13, 2019 AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in
treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has completed its previously announced acquisition of SentreHEART, Inc., a privately held developer of percutaneous left atrial appendage
management solutions.
About AtriCure, Inc.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide.
Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure s Isolator
Synergy Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure s AtriClip Left Atrial Appendage (LAA) Exclusion
About SentreHEART, Inc.
SentreHEART is a privately-owned
medical device company based in Redwood City, California. Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the LAA. The company is committed to clinical
evidence development and is currently sponsoring the FDA-approved prospective, multi-center, randomized controlled trial known as the aMAZE Trial. Information about the aMAZE Trial can be found at: